NR1I2 and breast cancer: Understanding whether SXR is pro- or anti-proliferative in breast cancers is very important for optimizing breast cancer therapies because many commonly used chemotherapeutic agents (tamoxifen, taxol, cyclophosphamide, cisplatin) are SXR activators.